

## Biocon Biologics, Voluntis to bring digital therapeutics for insulins

21 July 2020 | News

### Will Enable Access to Insulia®, an FDA-cleared & CE marked, Digital Therapeutic, for Insulin-dependent Type 2 Diabetes Patients



Biocon Biologics India Limited, a fully integrated 'pure play' biosimilars company, a subsidiary of Biocon Ltd., and Paris based Voluntis, a leader in digital therapeutics, have announced a global collaboration agreement between Biocon Biologics' subsidiary Biocon Sdn. Bhd., Malaysia and Voluntis to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy.

The licensing agreement will make Biocon Biologics one of the first insulins companies to offer a U.S. Food and Drug Administration-cleared and CE-marked, highly validated digital therapeutic product, Insulia®, to Type 2 diabetes patients, across several markets in the world. Insulia® provides automated insulin dose recommendations enabling people with diabetes to self-manage their condition and healthcare teams to remotely monitor progress.

Insulia® is the first digital therapeutic with regulatory clearance to provide automated titration recommendations for all types of basal insulins.

The demand for at-home treatment and telemedicine solutions is dramatically increasing around the world, with select healthcare systems offering reimbursement for patients eligible for digital therapeutic solutions.

Once developed, the Insulia® digital companion will be offered to people with Type 2 diabetes using Biocon Biologics' insulins, in key global markets. Going forward, by extending the Insulia® platform to its complete range of insulin products, including Recombinant Human Insulin, Insulin Glargine and Insulin Aspart, Biocon Biologics will create a comprehensive digital therapeutics portfolio for patients.